Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.

Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D

Open source

DOI: 10.1053/j.ajkd.2022.05.012
Published: 2023 Feb
Container: American journal of kidney diseases : the official journal of the National Kidney Foundation
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1053/j.ajkd.2022.05.012,
  title = {Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.},
  author = {Michael M and Groothoff JW and Shasha-Lavsky H and Lieske JC and Frishberg Y and Simkova E and Sellier-Leclerc AL and Devresse A and Guebre-Egziabher F and Bakkaloglu SA and Mourani C and Saqan R and Singer R and Willey R and Habtemariam B and Gansner JM and Bhan I and McGregor T and Magen D},
  year = {2023},
  journal = {American journal of kidney diseases : the official journal of the National Kidney Foundation},
  doi = {10.1053/j.ajkd.2022.05.012},
  url = {https://doi.org/10.1053/j.ajkd.2022.05.012}
}

RIS

TY  - JOUR
TI  - Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
AU  - Michael M
AU  - Groothoff JW
AU  - Shasha-Lavsky H
AU  - Lieske JC
AU  - Frishberg Y
AU  - Simkova E
AU  - Sellier-Leclerc AL
AU  - Devresse A
AU  - Guebre-Egziabher F
AU  - Bakkaloglu SA
AU  - Mourani C
AU  - Saqan R
AU  - Singer R
AU  - Willey R
AU  - Habtemariam B
AU  - Gansner JM
AU  - Bhan I
AU  - McGregor T
AU  - Magen D
PY  - 2023
JO  - American journal of kidney diseases : the official journal of the National Kidney Foundation
DO  - 10.1053/j.ajkd.2022.05.012
UR  - https://doi.org/10.1053/j.ajkd.2022.05.012
ER  -

APA

M, M., JW, G., H, S., JC, L., Y, F., E, S., AL, S., A, D., F, G., SA, B., C, M., R, S., R, S., R, W., B, H., JM, G., I, B., T, M., & D, M. (2023). Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.. American journal of kidney diseases : the official journal of the National Kidney Foundation. https://doi.org/10.1053/j.ajkd.2022.05.012

Source records

pubmed · retrieved 2026-09-26T01:41:34.257Z